Faculty profile

Alejandro Lazo-Langner

Back to faculty

Cross-Appointed Assistant ProfessorDepartment of Epidemiology and BiostatisticsWestern University

Alejandro Lazo-Langner

Cross-Appointed Assistant Professor

Department of Epidemiology and Biostatistics

Schulich School of Medicine & Dentistry

Western University

London, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
34 publications in the last five years, latest in 2026.
Senior (last) author on 8 recent papers, a sign of leading a research group.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

108

Publications

2,267

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Western University profile.

Latest papers

Primary thromboprophylaxis in patients with malignancy and central venous catheters: TRIM-Line randomized controlled trial - Design and rationale.
Thrombosis and haemostasis · 2026
DOACs vs warfarin in AF with comorbid CKD or valvular disease: a systematic review and meta-analysis.
Blood vessels, thrombosis & hemostasis · 2026 · senior author
Elevated on-treatment D-dimer level is associated with major bleeding during extended anticoagulation for venous thromboembolism.
Haematologica · 2026

All 108 publications

Latest funding

A Training Platform in Pragmatic Registry-Based Trials: Connecting Canada's Health, Data, and Biomanufacturing Sectors
CIHR · 2022 · Co-investigator
$3,479,320
A Training Platform in Pragmatic Registry-Based Trials: Connecting Canada's Health, Data, and Biomanufacturing Sectors
CIHR · 2022 · Co-investigator
$869,831
CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network
CIHR · 2020 · Co-investigator
$150,000

All 4 grants and awards

108 publications.

Primary thromboprophylaxis in patients with malignancy and central venous catheters: TRIM-Line randomized controlled trial - Design and rationale.

Wang TF, Ikesaka R, Mahé I, Hill D, Sperlich C, Tagalakis V, Shivakumar S, Leonard B, Cervi A, Kuruvilla P, Larose F, Matino D, Frosi Stella S, Séguin C, Al Raizah A, Le Gal G, Siegal DM, Delluc A, Mallick R, Lazo-Langner A, Wu C, Christopher D, Di Nisio M, Ageno W, Yazji B, Carrier M

Thrombosis and haemostasis2026

DOI: 10.1055/a-2963-4656 PMID: 42767263

DOACs vs warfarin in AF with comorbid CKD or valvular disease: a systematic review and meta-analysis.

Liang A, Wang C, Iansavitchene AE, Lazo-Langner A

Blood vessels, thrombosis & hemostasis2026Senior author

DOI: 10.1016/j.bvth.2025.100111 PMID: 41438731

Elevated on-treatment D-dimer level is associated with major bleeding during extended anticoagulation for venous thromboembolism.

Wang H, Kovacs MJ, Lazo-Langner A, Anderson DR, Kahn SR, Castellucci LA, Schmidt J, Elias A, Righini M, Ortel TL, Huisman MV, Carrier M, Mallick R, Rodger MA, Le Gal G, Wells PS, Xu Y

Haematologica2026

DOI: 10.3324/haematol.2026.300589 PMID: 42459131

Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial.

Saad M, Wang TF, Mallick R, Hill D, Lazo-Langner A, Tagalakis V, Wells PS, Carrier M

Thrombosis research2026

DOI: 10.1016/j.thromres.2026.109681 PMID: 41985366

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Castellucci LA, Chen VM, Kovacs MJ, Lazo-Langner A, Greenstreet P, Kahn S, Côté B, Schulman S, de Wit K, Douketis J

New England Journal of Medicine202652 citations

DOI: 10.1056/nejmoa2510703

Association Between Bariatric Surgery and the Long‐Term Risk for Venous Thromboembolism: A Population‐Based Matched Cohort Study

Simard C, Le Gal G, Lazo‐Langner A, Tagalakis V, Grewal K, Nguyen F, Wang T, Siegal DM, Anvari M, Doumouras AG

American Journal of Hematology20262 citations

DOI: 10.1002/ajh.70186

Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study

Ko AK, Milana L, Riva N, Bertu L, Bertoletti L, Beyer-Westendorf J, Carrier M, Delluc A, Grandone E, Kamphuisen P

Journal of Thrombosis and Haemostasis20261 citations

DOI: 10.1016/j.jtha.2026.05.014

Machine Learning for JAK2 Mutation Prediction in Erythrocytosis: Context Matters.

Chin-Yee B, Ho J, Lazo-Langner A, Hsia CC

Archives of pathology & laboratory medicine2025

DOI: 10.5858/arpa.2025-0207-le PMID: 41265684

Racial disparities in the incidence and risk factors of major bleeding during extended anticoagulant therapy for venous thromboembolism.

Omar D, Kovacs MJ, Lazo-Langner A, Anderson DR, Kahn SR, Castellucci LA, Schmidt J, Elias A, Righini M, Ortel TL, Huisman MV, Carrier M, Cénat JM, Mallick R, Rodger MA, Le Gal G, Wells PS, Xu Y

Journal of thrombosis and haemostasis : JTH2025

DOI: 10.1016/j.jtha.2025.07.026 PMID: 40769433

Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review.

Liu J, Chin-Yee B, Ho J, Lazo-Langner A, Chin-Yee IH, Iansavitchene A, Hsia CC

Blood advances2025

DOI: 10.1182/bloodadvances.2024015410 PMID: 39913688

A Training Platform in Pragmatic Registry-Based Trials: Connecting Canada's Health, Data, and Biomanufacturing Sectors

Co-investigatorCIHR2022Training Grant: Clinical Trials Training Platforms

Principal investigators: Garg, Amit; Basile, Erika; Bhatia, Rajan S; Clemens, Kristin K; Dixon, Stephanie N; Ethier, Jean-Francois; Fowler, Robert A; Gagnier, Joel J; Garrison, Scott R; Grimshaw, Jeremy M; Hohl, Corinne M; Ivers, Noah M; Jairath, Vipul; James, Matthew T; Jerath, Angela; Katz, Alan; Krzyzanowska, Monika K; LeBlanc, Annie; Lee, Douglas S; Mcalister, Finlay A; McGrail, Kimberlyn M; McIntyre, Lauralyn A; Mittmann, Nicole; Naylor, Kyla; Presseau, Justin; Schull, Michael J; Sontrop, Jessica M; Spence, Jessica; Swartz, Richard; Taljaard, Monica; Tangri, Navdeep; Udell, Jacob A; Weijer, Charles E; Zwarenstein, Merrick F

Keywords: Administrative Healthcare Data; Implementation Science; Methods; Pragmatic Clinical Trial; Randomized Controlled Trial; Training

$3,479,320

A Training Platform in Pragmatic Registry-Based Trials: Connecting Canada's Health, Data, and Biomanufacturing Sectors

Co-investigatorCIHR2022Training Grant: Clinical Trials Training Platforms - Indirect Costs

Keywords: Administrative Healthcare Data; Implementation Science; Methods; Pragmatic Clinical Trial; Randomized Controlled Trial; Training

$869,831

CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network

Co-investigatorCIHR2020Operating Grant: Clinical Research Infrastructure Support for COVID-19

Principal investigators: Kahn, Susan R; Rodger, Marc A

Keywords: Anticoagulation; Biomarkers; Deep Vein Thrombosis; Knowledge Translation; Outcomes Research; Patient Engagement; Pulmonary Embolism; Quality Of Care; Randomized Clinical Trial; Venous Thromboembolism

$150,000

CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network

Co-investigatorCIHR2015ICRH Community Development Program Grants

Principal investigators: Kahn, Susan R; Rodger, Marc A

$1,500,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Profile data last refreshed on November 9, 2025 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Alejandro Lazo-Langner

Research

Latest papers

Latest funding

Primary thromboprophylaxis in patients with malignancy and central venous catheters: TRIM-Line randomized controlled trial - Design and rationale.

DOACs vs warfarin in AF with comorbid CKD or valvular disease: a systematic review and meta-analysis.

Elevated on-treatment D-dimer level is associated with major bleeding during extended anticoagulation for venous thromboembolism.

Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial.

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Association Between Bariatric Surgery and the Long‐Term Risk for Venous Thromboembolism: A Population‐Based Matched Cohort Study

Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study

Machine Learning for JAK2 Mutation Prediction in Erythrocytosis: Context Matters.

Racial disparities in the incidence and risk factors of major bleeding during extended anticoagulant therapy for venous thromboembolism.

Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review.

A Training Platform in Pragmatic Registry-Based Trials: Connecting Canada's Health, Data, and Biomanufacturing Sectors

A Training Platform in Pragmatic Registry-Based Trials: Connecting Canada's Health, Data, and Biomanufacturing Sectors

CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network

CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network

Frequent collaborators

Marc Carrier

Bekim Sadikovic

Vicky Tagalakis

Benjamin Chin-Yee

Sam Schulman

Sudeep Shivakumar

Grégoire Le Gal

Tzu-Fei Wang

James Demetrios Douketis

Christopher Howlett

Shannon Bates

Ryan Zarychanski

Alejandro Garcia Horton

Amit Garg

Kerstin de Wit

Martha Louzada

Michael Kovacs

Ziad Solh

Peter Lawrence Gross

Sameer Parpia

Vinai Bhagirath

Deborah Siegal

Marc Rodger

Marc Rodger

Marc Afilalo

Nikhil Sangle

Michael Shkrum

Joan Knoll